naltrexone has been researched along with paroxetine in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (26.32) | 18.2507 |
| 2000's | 5 (26.32) | 29.6817 |
| 2010's | 7 (36.84) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Insel, TR; Winslow, JT | 1 |
| Keith, SJ; Nurnberg, HG; Paxton, DM | 1 |
| Gray, AM; Sewell, RD; Spencer, PS | 1 |
| Amiaz, R; Dannon, PN; Grunhaus, L; Schreiber, S; Stein, O | 1 |
| Bekkedal, M; Borkowski, C; Burgdorf, J; Panksepp, J; Turner, C | 1 |
| Grant, JE; Kim, SW | 1 |
| Baker, B; Baldini-Rossi, N; Hollander, E; Pallanti, S; Sood, E | 1 |
| Arranz, B; Arrojo, M; Becoña, E; Bernardo, M; Castells, X; Cunill, R; Flórez, G; Fonseca, F; Garriga, M; Goikolea, JM; González-Pinto, A; López, A; Sáiz, PA; San, L; Tirado-Muñoz, J; Torrens, M; Zorrilla, I | 1 |
| Becker, C; Becker, G; Boehlke, C; Buroh, S; Coune, B; Hercz, D; Joos, L; Meerpohl, JJ; Schwarzer, G | 1 |
4 review(s) available for naltrexone and paroxetine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacological treatments of pathological gambling.
Topics: Antidepressive Agents, Second-Generation; Behavior, Addictive; Bupropion; Comorbidity; Disruptive, Impulse Control, and Conduct Disorders; Dose-Response Relationship, Drug; Fluvoxamine; Gambling; Humans; Naltrexone; Outcome Assessment, Health Care; Paroxetine; Piperazines; Research Design; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders; Triazoles | 2005 |
Clinical practice guideline on pharmacological and psychological management of adult patients with an anxiety disorder and comorbid substance use.
Topics: Adult; Anxiety Disorders; Desipramine; Humans; Naltrexone; Paroxetine; Substance-Related Disorders | 2022 |
Pharmacological interventions for pruritus in adult palliative care patients.
Topics: Animals; Capsaicin; Cromolyn Sodium; gamma-Aminobutyric Acid; Humans; Naltrexone; Ondansetron; Palliative Care; Paroxetine; Receptors, Opioid; Rifampin; Zinc Sulfate | 2023 |
15 other study(ies) available for naltrexone and paroxetine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Serotonergic and catecholaminergic reuptake inhibitors have opposite effects on the ultrasonic isolation calls of rat pups.
Topics: Animals; Body Temperature; Catecholamines; Citalopram; Clomipramine; Desipramine; Flumazenil; Mazindol; Motor Activity; Naltrexone; Nortriptyline; Paroxetine; Piperidines; Rats; Rats, Inbred Strains; Serotonin Antagonists; Stress, Psychological; Ultrasonics; Vocalization, Animal | 1990 |
Consideration of the relevance of ethological animal models for human repetitive behavioral spectrum disorders.
Topics: Acepromazine; Animals; Antipsychotic Agents; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Ethology; Female; Horse Diseases; Horses; Humans; Naltrexone; Narcotic Antagonists; Obsessive-Compulsive Disorder; Opioid Peptides; Paroxetine; Reaction Time; Selective Serotonin Reuptake Inhibitors; Serotonin; Stereotyped Behavior; Stress, Psychological | 1997 |
The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds.
Topics: Abdominal Muscles; Acetic Acid; Amitriptyline; Analgesics; Animals; Antidepressive Agents; Cyclobutanes; Dothiepin; Male; Maprotiline; Mice; Muscle Contraction; Naloxone; Naltrexone; Narcotic Antagonists; Neprilysin; Neurotransmitter Uptake Inhibitors; Opioid Peptides; Pain Measurement; Paroxetine; Protease Inhibitors; Receptors, Opioid; Selective Serotonin Reuptake Inhibitors; Thiorphan | 1998 |
Resolution of treatment-refractory depression with naltrexone augmentation of paroxetine--a case report.
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Therapy, Combination; Female; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Paroxetine | 1999 |
Paradoxical effects of serotonin and opioids in pemoline-induced self-injurious behavior.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Drug Synergism; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Paroxetine; Pemoline; Rats; Rats, Sprague-Dawley; Reflex, Startle; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Social Behavior; Time Factors | 1999 |
Demographic and clinical features of 131 adult pathological gamblers.
Topics: Adult; Aged; Disruptive, Impulse Control, and Conduct Disorders; Double-Blind Method; Female; Gambling; Humans; Male; Middle Aged; Motivation; Naltrexone; Paroxetine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Socioeconomic Factors | 2001 |